Fiche société
Neuromed IRCCS
Traitements, essais et publications liés.
Traitements8programmes
Essais4liés
Publications12liées
SourceDBlocale
Traitements
8| Molécule | Indication / population | Phase | Objectif | Pays | Résultat |
|---|---|---|---|---|---|
| Circulating Biomarker for Amyotrophic Lateral Sclerosis (ALS)Description non affichée : incohérence de maladie détectée. Consultez l’essai clinique officiel associé. | Sclérose latérale amyotrophique | À vérifier | Ralentissement de la progression | Italy | À vérifier |
| MIGPHYSTREAT — Effectiveness of Multimodal Physical Therapy in MigraineINTRODUCTION: It is very common that migraine patients could refer neck pain during or after the pain phase of migraine, suggesting that migraine pathophysiological mechanisms could be effective in activating neck pain pathways and be part of the migraine attack. Due to the therapeutic effect of multimodal physical therapy (mobilization and/or manipulation plus exercises) on several pain conditions arising from articular and/or muscular structures such as neck pain, and given the close clinical, anatomical and pathogenetic bi-directional relationship between neck pain and migraine, it would be of interest to evaluate the effectiveness of the physical treatment of the neck region in migraine pain. PURPOSE: to evaluate the efficacy of a combined multimodal physical therapy approach plus usual care vs. usual care alone in subjects with episodic and chronic migraine with concomitant cervical musculoskeletal dysfunctions. STUDY DESIGN: this is a prospective, parallel group, randomized clinical trial. METHODS: A total of 56 subjects aged 18-65 who meet criteria for episodic or chronic migraine with concomitant cervical musculoskeletal dysfunctions will be randomly assigned to receive, musculoskeletal focused multimodal physical therapy (16 sessions over 8 weeks) plus usual care treatment vs. usual care alone. CONFLICT OF INTEREST: not declared. | Migraine | Non applicable | Traitement symptomatique | Italy | À vérifier |
| peripheral blood withdrawalInflammatory synaptopathy is a prominent pathogenic process in multiple sclerosis (MS) induced by imbalanced immune system homeostasis. Its persistence causes excitotoxic neuronal damage, leading to motor and cognitive deficits. Although many advances have been made in MS treatment, the development of effective strategies for managing disease progression driven by excitotoxic synaptic dysfunctions is of great significance. Gut dysbiosis is commonly associated with both MS and obesity and high-fat diet (HFD) can exacerbate disease by acting on gut microbiota. Since gut microbiota can shape the immune response and brain functions, we propose to target gut dysbiosis by dietary supplementation of prebiotics and probiotics (Pre-Pro) to treat synaptopathy in both human and experimental model of MS, even when exacerbated by HFD. Overall, this project aims at unveiling the anti-inflammatory and neuroprotective pathways activated by Pre-Pro supplementation to modulate the immune-synaptic axis. | SEP | Non applicable | Neuroprotection + Immunomodulation + Ralentissement de la progression | Italy | À vérifier |
| Transcranial Magnetic Stimulation (TMS)Background: Transcranial Magnetic Stimulation (TMS) is a technique based on the principles of electromagnetic induction. It applies pulses of magnetic radiation that penetrate the brain tissue, and it is a non-invasive, painless and practically innocuous procedure. Previous studies advocate the therapeutic capacity of TMS in several neurodegenerative and psychiatric processes, both in animal models and in human studies. Its uses in Parkinson's disease, Alzheimer's disease and in Huntington's chorea have shown improvement in the symptomatology and in the molecular profile, and even in the cellular density of the brain. Consequently, the extrapolation of these TMS results in the aforementioned neurodegenerative disease to other entities with etiopathogenic and clinical analogy would raise the relevance and feasibility of its use in multiple sclerosis (MS). The overall objective will be to demonstrate the effectiveness of the TMS in terms of safety and clinical improvement, as well as to observe the molecular changes in relation to the treatment. Methods and design: Phase I clinical trial, unicentric, controlled, randomised, single blind. A total of 90 patients diagnosed with relapsing-remitting multiple sclerosis (RRMS) who meet all the inclusion criteria and do not present any of the exclusion criteria that are established and from which clinically evaluable results can be obtained. The patients included will be assigned under the 1:1:1 randomization formula, constituting three groups for the present study: 30 patients treated with natalizumab + white (placebo) + 30 patients treated with natalizumab + TMS (1 Hertz) + 30 patients treated with natalizumab + TMS (5 Hertz). Discussion: Results of this study will inform on the efficiency of the TMS for the treatment of MS. The expected results are that TMS is a useful therapeutic resource to improve clinical status (main parameters) and neurochemical profile (surrogate parameters); both types of parameters will be checked. | SEP | Non applicable | Traitement symptomatique | Italy | À vérifier |
| Circulating Biomarker for Amyotrophic Lateral Sclerosis (ALS)Description non affichée : incohérence de maladie détectée. Consultez l’essai clinique officiel associé. | Sclérose latérale amyotrophique | À vérifier | Ralentissement de la progression | Italy | À vérifier |
| Transcranial Magnetic Stimulation (TMS)Background: Transcranial Magnetic Stimulation (TMS) is a technique based on the principles of electromagnetic induction. It applies pulses of magnetic radiation that penetrate the brain tissue, and it is a non-invasive, painless and practically innocuous procedure. Previous studies advocate the therapeutic capacity of TMS in several neurodegenerative and psychiatric processes, both in animal models and in human studies. Its uses in Parkinson's disease, Alzheimer's disease and in Huntington's chorea have shown improvement in the symptomatology and in the molecular profile, and even in the cellular density of the brain. Consequently, the extrapolation of these TMS results in the aforementioned neurodegenerative disease to other entities with etiopathogenic and clinical analogy would raise the relevance and feasibility of its use in multiple sclerosis (MS). The overall objective will be to demonstrate the effectiveness of the TMS in terms of safety and clinical improvement, as well as to observe the molecular changes in relation to the treatment. Methods and design: Phase I clinical trial, unicentric, controlled, randomised, single blind. A total of 90 patients diagnosed with relapsing-remitting multiple sclerosis (RRMS) who meet all the inclusion criteria and do not present any of the exclusion criteria that are established and from which clinically evaluable results can be obtained. The patients included will be assigned under the 1:1:1 randomization formula, constituting three groups for the present study: 30 patients treated with natalizumab + white (placebo) + 30 patients treated with natalizumab + TMS (1 Hertz) + 30 patients treated with natalizumab + TMS (5 Hertz). Discussion: Results of this study will inform on the efficiency of the TMS for the treatment of MS. The expected results are that TMS is a useful therapeutic resource to improve clinical status (main parameters) and neurochemical profile (surrogate parameters); both types of parameters will be checked. | SEP | Phase 1 | Traitement symptomatique | À vérifier | |
| MIGPHYSTREAT — Effectiveness of Multimodal Physical Therapy in MigraineINTRODUCTION: It is very common that migraine patients could refer neck pain during or after the pain phase of migraine, suggesting that migraine pathophysiological mechanisms could be effective in activating neck pain pathways and be part of the migraine attack. Due to the therapeutic effect of multimodal physical therapy (mobilization and/or manipulation plus exercises) on several pain conditions arising from articular and/or muscular structures such as neck pain, and given the close clinical, anatomical and pathogenetic bi-directional relationship between neck pain and migraine, it would be of interest to evaluate the effectiveness of the physical treatment of the neck region in migraine pain. PURPOSE: to evaluate the efficacy of a combined multimodal physical therapy approach plus usual care vs. usual care alone in subjects with episodic and chronic migraine with concomitant cervical musculoskeletal dysfunctions. STUDY DESIGN: this is a prospective, parallel group, randomized clinical trial. METHODS: A total of 56 subjects aged 18-65 who meet criteria for episodic or chronic migraine with concomitant cervical musculoskeletal dysfunctions will be randomly assigned to receive, musculoskeletal focused multimodal physical therapy (16 sessions over 8 weeks) plus usual care treatment vs. usual care alone. CONFLICT OF INTEREST: not declared. | Migraine | Non applicable | Traitement symptomatique | Italy | À vérifier |
| peripheral blood withdrawalInflammatory synaptopathy is a prominent pathogenic process in multiple sclerosis (MS) induced by imbalanced immune system homeostasis. Its persistence causes excitotoxic neuronal damage, leading to motor and cognitive deficits. Although many advances have been made in MS treatment, the development of effective strategies for managing disease progression driven by excitotoxic synaptic dysfunctions is of great significance. Gut dysbiosis is commonly associated with both MS and obesity and high-fat diet (HFD) can exacerbate disease by acting on gut microbiota. Since gut microbiota can shape the immune response and brain functions, we propose to target gut dysbiosis by dietary supplementation of prebiotics and probiotics (Pre-Pro) to treat synaptopathy in both human and experimental model of MS, even when exacerbated by HFD. Overall, this project aims at unveiling the anti-inflammatory and neuroprotective pathways activated by Pre-Pro supplementation to modulate the immune-synaptic axis. | SEP | Non applicable | Neuroprotection + Immunomodulation + Ralentissement de la progression | Italy | À vérifier |
Essais cliniques
4| Molécule | Indication / population | Phase | NCT | Titre | Statut |
|---|---|---|---|---|---|
| peripheral blood withdrawal | SEP | Non applicable | NCT05779449 | Pre-Pro-MS — Targeting the Gut Dysbiosis to Treat Inflammation-driven Synaptopathy in MS | UNKNOWN |
| MIGPHYSTREAT — Effectiveness of Multimodal Physical Therapy in Migraine | Migraine | Non applicable | NCT05226559 | MIGPHYSTREAT — Effectiveness of Multimodal Physical Therapy in Migraine | UNKNOWN |
| Transcranial Magnetic Stimulation (TMS) | SEP | Phase 1 | NCT04062331 | Transcranial Magnetic Stimulation (TMS) in Multiple Sclerosis | UNKNOWN |
| Circulating Biomarker for Amyotrophic Lateral Sclerosis (ALS) | Sclérose latérale amyotrophique | À vérifier | NCT03088839 | Circulating Biomarker for Amyotrophic Lateral Sclerosis (ALS) | UNKNOWN |
Publications
12| Molécule | Indication / population | Titre | Journal | Date |
|---|---|---|---|---|
| Circulating Biomarker for Amyotrophic Lateral Sclerosis (ALS) | Systemic immune-metabolic interactions in patients with amyotrophic lateral sclerosis: correlations of plasma cytokines with metabolic status. | Amyotrophic lateral sclerosis & frontotemporal degeneration | ||
| Transcranial Magnetic Stimulation (TMS) | Reward circuitry predicts the effects of fMRI-guided accelerated prolonged iTBS in treatment-resistant depression. | Psychiatry research | ||
| Transcranial Magnetic Stimulation (TMS) | Age-related differences in motor learning, sensorimotor neurochemistry, and cortical reactivity co-occur but are dissociated. | Neurobiology of aging | ||
| Transcranial Magnetic Stimulation (TMS) | Mechanisms of taVNS-induced working memory enhancement: a multimodal fNIRS-HRV-MEP study. | Cognitive neurodynamics | ||
| Circulating Biomarker for Amyotrophic Lateral Sclerosis (ALS) | A Blood-Derived Factor Rescues ALS: Platelet Factor 4 Activates OPTN-Dependent Autophagy to Clear SOD1 Aggregates Independently of PINK1. | Advanced science (Weinheim, Baden-Wurttemberg, Germany) | ||
| Circulating Biomarker for Amyotrophic Lateral Sclerosis (ALS) | Molecular Mechanisms of Neurodegenerative Diseases: Emerging Biomarkers and Therapeutic Targets. | Brain sciences | ||
| Transcranial Magnetic Stimulation (TMS) | Spinal cord stimulation for concurrent improvement of consciousness and spasticity following severe traumatic brain injury: a case study. | Frontiers in neuroscience | ||
| Transcranial Magnetic Stimulation (TMS) | Real-Time Brain-State-Coupled Corticocortical Paired Associative Stimulation of Cognitive Networks. | The Journal of neuroscience : the official journal of the Society for Neuroscience | ||
| Transcranial Magnetic Stimulation (TMS) | A network-based brain stimulation paradigm for alcohol use disorder with co-occurring major depressive disorder: a mini review targeting the ventral attention network. | Frontiers in neurology | ||
| Transcranial Magnetic Stimulation (TMS) | Spatiotemporal Brain Dynamics of Transitive and Intransitive Action Observation. | Human brain mapping | ||
| Circulating Biomarker for Amyotrophic Lateral Sclerosis (ALS) | Anchoring ALS Prognosis: Neurofilament Light Chain Outperforms Inflammatory, Metabolic, and CNS Barrier Biomarkers in the METABALS Cohort. | Molecular neurobiology | ||
| Circulating Biomarker for Amyotrophic Lateral Sclerosis (ALS) | Multimodal analysis of cell-free DNA identifies epigenetic biomarkers for amyotrophic lateral sclerosis diagnosis and progression. | The Journal of clinical investigation |